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Abstract
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Our quest to isolate and characterize natural products with in vitro solid tumor selectivity is driven
by access to repositories of Indo-Pacific sponge extracts. In this project an extract of a species of
Haplosclerida sponge obtained from the US NCI Natural Products Repository displayed, by in
vitro disk diffusion assay (DDA) and IC50 determinations, selective cytotoxicity with modest
potency to a human pancreatic cancer cell line (PANC-1) relative to the human lymphoblast
leukemia cell line (CCRF-CEM). Two brominated indoles, the known 6-bromo conicamin (1) and
the new derivative, 6-Br-8-keto-conicamin A (2), were identified and 2 (IC50 1.5 μM for the
natural product vs 4.1 μM for the synthetic material) was determined to be responsible for the
cytotoxic activity of the extract against the PANC-1 tumor cell line. The new natural product and
ten additional analogs were prepared for further SAR testing.
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1. Introduction
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We believe that the study of bioactive natural products from sponges obtained within the
Indonesian Coral Triangle, called by some the “biodiversity bullseye,” represents an
underexplored, rich opportunity. One example of a significant result obtained from
exploration of the region is that manzamine A, a complex sponge-derived antimalarial
alkaloid1 (also a putative sponge-associated bacterial product)2 and subject of sustained
investigation,3 can be isolated in large amounts from several Indonesian sponges. Motivated
by this outcome, we continue to evaluate sponge extracts from repositories rich in
Indonesian sponge taxa. Currently, these resources consist of: 558 alcohol preserved sponge
samples collected by the UC Santa Cruz team, and 230 Indonesian marine sponge extracts
provided to UCSC from the NCI-DTP repository.4 An important filter to prioritize work on
these samples utilizes a primary in vitro disk diffusion assay (DDA) developed at the Henry
Ford Cancer Institute. This assay flags samples based on selectivity and potency against five
solid tumor cell lines (human pancreatic cancer PANC-1, human ovarian OVCAR-5, human
lung H125, human hepatoma HepG2, and human brain U251N) compared to responses from
two normal cell lines (murine and human hematopoietic progenitor cells, CFU-GM) and a
leukemia cell line (CEM).5 The five cancers represented by these cell lines account for 74%
of all solid tumor cancers (1,658,000 cases per year in the US) and 70% of solid tumor
mortality (589,000 deaths per year in the US).6 The output from our primary screen is
quantified by measuring the radius of cell death after exposure to extract or compounds,
where selectivity is defined by a differential zone of inhibition between cell lines.
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The first phase of our effort to evaluate the sample library described above has been to
pinpoint extracts and compounds with solid tumor selectivity in the DDA5 (those with a >
6.5 mm difference in zone of inhibition for solid tumor cell lines vs. either bone marrow
progenitor or leukemia cells). During the last two years, 120 of the UCSC sponges along
with 136 organic extracts of the NCI-DTP sponge samples have been extracted, prefractionated, and tested. The overall priority hit rate is low (≅ 1%), but there have been a
number of positive outcomes using this approach with Indonesian sponges, including our
recently published finding that makaluvamine J can be isolated from both UCSC and DTP
collections of Zyzzya fuliginosa. This compound exhibits solid tumor selectivity for both
PANC-1 (IC50 = 54 nM) and OVCAR-5 (IC50 = 120 nM) cells.7 The general steps involved
in the discovery process (Chart 1) have now been applied to the 256 samples in this
assemblage and one chosen for detailed analysis has provided the results reported herein,
while outcomes from the remaining sponge active extracts will be published elsewhere.
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2. Results and discussion
The extract of Oceanapia sp. C011027 (from the NCI-DTP repository) was prioritized for
investigation in this study using the soft agar disk diffusion assay (DDA) whose results are
shown in Table 1. The DDA measures a zone of inhibition (in mm) for a sample diffusing
from a disk placed at the edge of the petri dish containing tumor cells embedded in a soft
agar matrix. Samples considered to have high cytotoxicity exhibit a zone of inhibition ≥ 20
mm in any of the cell lines, which included five solid tumor cell lines, a leukemia line
(CEM), and bone marrow progenitor cells (CFU-GM). Some benchmark results are
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provided by the activities for two clinical drugs, gemcitabine and 5-fluorouracil, which are
powerful cytotoxins against almost all of the eight cell lines screened. Both drugs also
displayed selectivity between one or more solid tumor cell lines and either the leukemia or a
normal cell surrogate (zone of inhibition difference > 7mm, indicated by bold numbers in
Table 1). The best response for the Oceanapia sp. extract was against PANC-1 (zone of
inhibition = 23 mm) which represented selective cytotoxicity relative to both CEM and
murine CFU-GM cells (Δinhibition zone = 10 mm and 7 mm, respectively). These results
prompted creation of an HPLC peak library that was screened in the DDA and the active
fractions were further evaluated by MSn and NMR. Subsequent isolation afforded the known
Suberites sponge compound, 6-Br-concamin (1)8 and an unreported compound 6-Br-8-ketoconcamin A (2) shown in Fig. 1. While 1 was not cytotoxic by the DDA, synthetic 2 (2a) at
112 nmol/disk exhibited a zone of inhibition = 28 mm against PANC-1 and 33 mm against
MCF-7, each with a greater than 20 mm differential between CEM and CFU-GM cell lines.
We also synthesized a family of bromoindole compounds bearing quaternary ammonium
substituents including the 5-Br analog of 2 (3), which was also active in the DDA with an
inhibition zone of 20 mm against PANC-1 and 33 mm against MCF-7, again selective
between these solid tumor cell lines and CEM and CFU-GM. Eight other synthetic
intermediates employed in the syntheses were inactive in the DDA. Additional elements of
the study included two comprehensive evaluations: (a) unraveling NMR δ values to facilitate
the placement of a halogen at the 5 vs. 6 position of an indole ring, and (b) using the
PANC-1 IC50’s to define a useful SAR pattern for this indole scaffold.
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A DDA active fraction (data not shown herein) from the Oceanapia peak library actually
contained a mixture of two compounds with m/z of 279 and 295, each having an M+2 peak
of equivalent height, indicating the presence of a single bromine atom. The two compounds
briefly discussed above, known 6-Br-conicamin (1)8 and new 6-Br-8-keto-conicamin (2),
were separated by semi-preparative reversed phase HPLC using 21:89 acetonitrile:H2O.
Neither fraction formed adducts in ESI mass spectrometry when spiked with sodium or
potassium, consistent with a native positive charge. Accurate mass measurement gave two
nearly identical molecular formulas differing by an oxygen: 1: ESI m/z 279.0467 [M]+
(calcd for C13H16N279Br, 279.0491) and 2: ESI m/z 295.0419 [M]+ (calcd for
C13H16N2O79Br, 295.0441). The mass data from 1 coupled with a 1H NMR spectrum
showing four indole ring protons, two vinyl protons and a singlet for nine protons near δ3
allowed 1 to be identified as 6-bromo-conicamin (1) by dereplication. Despite the structural
similarity implied by both MS and NMR data, the structure of 2 had not been reported in the
literature. Inspection of the 13C NMR spectrum of 2 revealed that the vinyl carbons in 1
were not present and were replaced by a ketone at δC 185.4 and a CH2 at δC 66.1,
respectively (Table 1). The HMBC correlations observed from the N-trimethyl protons at δH
3.33 to the CH2 at δC 66.1 but not the carbonyl at δC 185.4 suggested a ketone-methylenetrimethylamine motif. These data coupled with the remaining long range correlations
observed by gHMBCAD enabled provisional assignment of 2. However, placement of the Br
at either C-5 or C-6 could not be confidently assigned. This ambiguity was resolved by
additional NMR δ analyses discussed next along with NMR data comparison to synthesized
products including 6-bromo-8-keto-conicamin A (2a), and 5-bromo-8-keto-conicamin A (3).
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Finalizing the Br atom placement in natural product 2 at C-5 vs. C-6 (Fig. 1) should be
trivial as it involves assigning the relative position of an indole AB spin system as proximal
or distant to the NH. Unfortunately, our attempts to obtain NOE or HMBC correlations to
the NH residue for a definitive resolution were unsuccessful. Alternatively, a literature
search to provide NMR δH and δC values distinctive for these isomeric frameworks provided
diagnostic patterns shown in Figure 1. First, the δH shifts at H-4/H-5 (3JH-H portion), and
H-7 for a 6-bromo isomer are different vs. those at H-4, and H-6/H-7 (3JH-H portion) for a 5bromo isomer as shown in Fig. 2. A key is that the relative ΔδH for the o-proton doublets is
small (≅ 0.2 ppm) for the 5-Br isomer but large (> 0.5 ppm) for the 6-Br isomer. Second, the
δC at C-3a is deshielded by approximately 3 ppm in the 5-Br relative to that of the 6-Br
indole.9, 10 The observed patterns for 2 matched that of the lower example in Figure 2:
vicinal proton ΔδH = 0.69 and δC-3a = 124.3. Correspondingly, the synthetic compounds
obtained as described in the next section further supported these observations. For example,
the spectrum of 3 matched that of the upper example in Figure 2: the vicinal proton ΔδH =
0.20 and δC-3a = 127.7 (see NMR data in Table 1, supplemental Figs. S9 & S10), and the
data of the commercially available aldehyde 5 matched that of the lower example in Figure
2: the vicinal proton ΔδH = 0.67 and δC-3a = 123.1.
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The process to obtain compound 2 and other analogs by synthesis is shown in Scheme 1.
Two indole-3-carboxaldehydes, 4 and 5, were used as separate starting materials to provide
the oxotryptamine synthons 10 and 11. While the yield of the cyanohydrin silylether 6 from
4 match that in the literature (60%), the yield of 7 from 5 was poor (20%) vs that in the
literature for the 5-Br analog (88%).11 Oxidation of both 6 and 7 via DDQ provided high
yields of 8 (83%) and 9 (60%).11 Hydrogenation of 8 afforded 10 in good yield after workup
(76%) and reduction of 9 provided the first route to 11.12 Bromination of the ketotryptamine synthon 10 proceeded in a straightforward fashion, producing the bromo-ketotryptamines 11 and 12 which were separated by reversed phase HPLC.13 We used 11
prepared from 5 to confidently distinguish between the 5- and 6-bromo isomers (11 and 12)
prepared via bromination of 10. NMR spectroscopic experiments on the commercially
obtained 5 assured correct assignment (see SI figures S34–38). The final steps involved
methylation of 10, 11, or 12 to respectively afford 13, 2a, or 3. Performing these reactions
with a reduced molar ratio of methyl iodide provided the dimethyl analogs 14, 15, or 16
from 11, 12, or 10, respectively as minor products. The compounds 2a, 11, or 14 were
produced in duplicate from either 5 or 10 as starting material and were equivalent in their
spectroscopic and bioassay properties.
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The synthetic work to prepare 2 and its analogs provided additional information to probe the
structure-activity relationship describing the cytotoxicity of Br-indoles. Based on our DDA
and IC50 screening of the intermediates and products from the synthesis, only the
compounds most similar to 2 (such as 3 and 13) possessed notable cytotoxic activity as
shown in Tables 1 and 3. The DDA data (Table 1) indicates similar solid tumor selectivity
for 2 and 3 in comparison to the two therapeutic standards. The IC50 data (Table 3) reveals
that a quaternary amine functionality is vital for low uM activity against PANC-1 cells,
which is on a par with that of the two therapeutic standards, 5-flourouracil and gemcitabine.
Also, the presence of the Br atom at C-5 or C-6 on the indole ring and the keto group at C-8
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are significant factors in the IC50 activity of 2 and 3. Interestingly, relative to 2, the primary
amines (compound 10–12) and tertiary amines (compounds 14 – 16) were inactive in both
the DDA and the IC50 determinations. In addition, 13, which lacks a Br, was not selective in
the DDA screen and was an order of magnitude less potent vs. 2 against PANC-1 cells based
on IC50 data. While the position of the Br (at C-5 or C-6) is less important, it was the 6bromo-8-keto-conicamin (2) that exhibited the best DDA selectivity for PANC-1 and
MCF-7, and greatest potency against PANC-1 (IC50 data against MCF-7 were not
measured). Overall, the low micromolar in vitro activity of 2 against the PANC-1 cell line
(IC50 1.5 μM for the natural product vs 4.1 μM for the synthetic material) is exciting and is
similar to that of the clinical therapeutics (5FU: IC50 = 7.0 μM; gemcitabine: IC50 = 0.02
μM).

3. Conclusion
Author Manuscript
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The halogenated indole moiety found in 2 has been observed in a number of metabolites
from marine macro- and microorganisms, including the topsentins,9 aplysinopsins,10
dragmacidins,16 hypaphorines,17 didemnimides,18 and nakijinamines.8 Thorough reviews of
marine-derived indole alkaloids and their activities has been published elsewhere.19,20 The
bioactivity of these compounds is diverse: cytotoxicity, antibacterial activity, anti-fungal
activity, histamine receptor agonism, and neurotransmitter receptor affinity. The quaternary
amine functionality found in 2 is rare, but there are examples of bioactive natural products
containing this cationic residue attached to a halogenated indole scaffold (Fig. 3). A
prenylated indole from a bryozoan with moderate nAChR activity prompted medicinal
chemistry efforts in which some analogs (e.g. 18) attained high nanomolar affinity for a
variety of nAChR subtypes.21 The results of this study are modest, yet the in vitro
cytotoxicity of 2 against the PANC-1 cell line exceeds that reported for 5-FU and
gemcitabine, which are the primary constituents of the current standards of care for
pancreatic cancer.14, 15 The structure of 2 was confirmed by synthesis and a number of
analogs were made using methodology originally developed for the syntheses of the
rhopaladins, dragmacidins, and almazoles.11, 12, 13 The quaternary amine functionality and
bromination of the indole ring of 2 was critical for activity against PANC-1. The new small
molecule discovered in this work highlights the value of continued pursuit of achiral marine
natural products and the effectiveness of continued screening using the NCI Developmental
Therapeutics Program extract library. Overall, the lack of small molecule therapies to treat
pancreatic cancer makes the results presented in Table 3 reasonably significant.

4. Experimental
Author Manuscript

4.1 General experimental procedures
UV spectra were measured with Thermo Ultimate 3000 DAD. IR spectra were measured
with a Perkin-Elmer Spectrum One FTIR spectrometer. Analytical LC-MS analysis was
performed on samples at a concentration of 10 mg/mL for crude extracts and 1 mg/mL for
pure compounds, using a 150 × 4.60 mm 5 μm C18 Phenomenex Luna column in
conjunction with a guard column and 4.0 × 3.0 mm C18 cartridge (Phenomenex, Inc.). 20
uL volumes of sample were injected onto the column using Waters 717 autosampler, with a
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flow rate of 1 mL/min provided by two Waters 515 HPLC pumps. The eluent was split
between an Applied Biosystems Mariner 5200 electrospray ionization time-of-flight (ESITOF) mass spectrometer and a Waters 996 photodiode array (PDA) UV detector in line with
a SEDERE 75 evaporative light scattering detector (ELSD). Optical rotations were
performed on a JASCO P-2000 polarimeter; the average of 10 measurements is reported,
each with 10 second digital integration time and 12 second cycle time. All NMR
experiments were run on a Varian Unity spectrometer (500 and 125 MHz for 1H and 13C,
respectively) or Varian INOVA spectrometer (600 and 150 MHz for 1H and 13C,
respectively) equipped with a cryoprobe. High accuracy mass spectrometry measurements
were recorded using an Applied Biosystems Mariner 5200 electrospray ionization time of
flight (ESI-TOF) mass spectrometer. Synthetic procedures were either performed via
Schlenk line with nitrogen or via balloon and septa techniques with argon. Flash
chromatography was performed using a Biotage Isolera Prime fraction collector with a 100 g
silica gel 60 column.
4.2. Biological material
The sponge Oceanapia sp. C011027 (phylum Porifera, class Demospongia, order
Haplosclerida) was collected at 10 m depth off the coast of Sulawesi, Indonesia. Sample
collection and identification was done by the Coral Reef Foundation under contract to the
National Cancer Institute (National Institutes of Health). A taxonomic voucher specimen
(number 0CDN1333) was deposited at the Smithsonian Institution in Suitland, MD (USA).
4.3. Compound isolation

Author Manuscript
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After extract C011027 demonstrated solid tumor selective activity, an HPLC peak library
was generated to determine the active constituents. The extract was fractionated using a 250
× 10 mm Phenomonex Luna C18 5μm semi-preparative column equipped with an analytical
guard column (4.0 × 3.0 mm C18 cartridge) and two Waters 515 HPLC pumps. The eluent
was monitored by a Waters 996 detector before being fractionated by a Gilson 215 Liquid
Handler that generated one fraction per minute. A Waters 717 autosampler injected 100 uL
of extract at 70 mg/mL onto the column; the first gradient 10:90 acetonitrile:H2O was held
for 1 minute, then linearly shifted to 100:0 acetonitrile:H2O over 29 minutes, and finally
held at 100:0 acetonitrile:H2O for 10 minutes. Fractions H16 and H17 were the only
fractions with significant zones of inhibition when evaluated in the DDA. These contained a
mixture of 1 and 2. Compounds 1 and 2 were separated using the following isocratic
conditions: 21:79 acetonitrile:H2O with tR = 12.5 and 15.5, respectively. Note that the
charge of these compounds leads to significant tailing and inconsistent retention times over
longer timescales (i.e. weeks). This can be mitigated to some extent by using TFA in the
mobile phase. Fraction collection was done manually using the same column as above with
two Waters 510 HPLC pumps, a Waters Model 680 gradient controller, and an ABI
Analytical Spectroflow 783 UV detector monitoring at 230nm.
4.3.1. 6-bromo-conicamin (1)—HAESIMS m/z 279.04667 [M]+ (calcd for
C13H16N279Br, 279.04914). NMR spectra were in accordance with literature.8
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4.3.2. 6-bromo-8-keto-conicamin (2)—Light pink crystalline solid; UV (MeCN:H2O)
209, 247, 271, 308 nm; IR (film) υmax 3438, 3250, 1637, 1520, 1443, 1414, 1384, 1048,
891, 595 cm−1; 1H NMR (DMSO-d6, 600 MHz) δ 8.58 (1H, bs, H-2), 8.08 (1H, d, J = 8.5
Hz, H-4), 7.77 (1H, s, H-7), 7.39 (1H, dd, J = 1.3, 8.5 Hz, H-5), 4.99 (2H, s, H-1′), 3.33
(9H, s, N-(CH3)3); 13C NMR (DMSO-d6, 150 MHz) δ 185.4 (C, C-2′), 138.1 (C, C-7a),
136.9 (CH, C-2), 125.4 (CH, C-5), 124.3 (C, C-3a), 122.7 (CH, C-4), 115.9 (C, C-6), 115.6
(CH, C-7), 114.6 (C, C-3), 66.1 (CH2, C-1′), 53.5 (CH3, N-(CH3)3); HAESIMS m/z
295.04191 [M]+ (calcd for C13H16N2O79Br, 295.04405).
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4.4.1. 2-(1H-indole-3-yl)-2-(trimethylsiloxy)acetonitrile (6)—Procedure adapted
from Janosik.11 To a solution of 1.16g 1H-indol-3-yl-carboxaldehyde (Combi-Blocks, San
Diego, CA, USA) in 10mL acetonitrile, 1.3 mL TMSCN was added. The reaction solution
was heated and maintained at reflux for 2 h before cooling. After evaporation of the solvent,
reaction products were purified from the resulting oil using flash chromatography (isocratic
80:20 hexane-ethyl acetate) to afford 6 (1.2g, 65%) as a lime-green oil. MS (ESI) 243 m/z
(M-H)−. NMR data were in accordance with literature.

Author Manuscript

4.4.2. 2-(6-bromo-1H-indol-3-yl)-2-(trimethylsiloxy)acetonitrile (7)—Adapted from
procedure for 5-bromo isomer from Janosik.11 To a solution of 1.08g 6-bromo-1H-indol-3yl-carboxaldehyde (Tokyo Chemical Industry, Tokyo, Japan) in 10mL DME, 0.73 mL
TMSCN was added. The reaction solution was heated and maintained at reflux for 2.5 h
before cooling. After evaporation of the solvent, reaction products were purified by flash
chromatography (hexane-ethyl acetate gradient) to afford 7 (0.35g, 19%) as a light yellow
oil. 1H NMR (DMSO-d6, 600 MHz) δ11.45 (1H, S), 7.63 (1H, d, J = 1.9), 7.60 (1H, d, J =
8.4), 7.56 (1H, d, J = 2.6), 7.24 (1H, dd, J = 8.5, 1.8), 6.18 (1H, s), −0.11 (9H, s); 13C NMR
(DMSO-d6, 150 MHz) δ 137.4, 126.0, 123.8, 122.5, 120.4, 119.9, 114.7, 114.6, 111.0, 56.8,
−0.23. MS (ESI) 321 and 323 m/z (M-H)−.
4.4.3. 1H-indol-3-carbonyl cyanide (8)—A solution of DDQ (1.21 g, 5.3 mmol) in 60
mL dioxane was added dropwise by addition funnel to a stirring solution of 6 (1.18 g, 4.8
mmol) in 10 mL dioxane. After 2.5 h the reaction mixture was filtered and the filtrate dried
to a purple-black solid. Flash chromatography (DCM-EtOAc gradient) afforded 8 (0.68g,
83%) as a yellow oil. MS (ESI) 171 m/z [M+H]+. NMR data were in accordance with
literature.
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4.4.4. 6-bromo-1H-indol-3-carbonyl cyanide (9)—The procedure above was used
with 6-bromo-indole-TMS (7) (0.35g, 1.1 mmol) and DDQ (0.27g). Flash chromatography
(hexanes-EtOAc gradient) afforded 9 (0.15g, 55%) as a fluffy yellow solid. MS (ESI)
247/249 [M-H]−.
4.4.5. 8-keto-tryptamine (10)—To 150 mg of 10% Pd/C, a solution of 1 mmol of 1Hindol-3-carbonyl cyanide (8) in 10 mL acetic acid was added. Hydrogen gas was added via
balloon and septum. After 15 h, the reaction mixture was filtered using diatomaceous earth
and the filtrate was dried, resuspended in water, basified, then extracted with ethyl acetate to
give 0.76 mmol of the free base 10. NMR data were in accordance with literature.
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4.4.6. 6-bromo-8-keto-tryptamine (11)—The first route to 11 employed the procedure
above (10) using 9 as starting material. The second route was performed as follows. To a
stirring solution of β-keto-tryptamine (10) in 1:1 formic acid:acetic acid, 1.2 equivalents of
Br2 was added dropwise. After 24 h, the reaction mixture was dried and subjected to
reversed phase HPLC to afford 11 and 12. 1H NMR (DMSO, 500 MHz) δ 12.47 (1H, s,
NH), 8.52 (1H, d, J = 3 Hz, H-2), 8.1 (1H, d J = 8.4 Hz, H-4), 7.74 (1H, s, H-7), 7.4 (1H, d J
= 8.5 Hz, H-5), 4.38 (2H, s, H-9); 13C NMR (DMSO, 125 MHz) δ 187 (CO), 137.5, 136,
123.3, 124.1, 122.6, 115.6, 115.8, 115.2, 113.1, 44.1. MS (ESI) 252/254 [M+H]+.
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4.4.7. 5-bromo-8-keto-tryptamine (12)—The second procedure above for 11 also
afforded 12 by reversed phase HPLC. 1H NMR (DMSO, 500 MHz) δ 8.54 (1H, d J=3.0 Hz,
H-2), 8.29 (1H, d J = 1.8 Hz, H-4), 7.53 (1H, d J = 8.6 Hz, H-7), 7.41 (1H, dd J = 8.6, 1.7
Hz, H-6), 4.39 (2H, s, H-9); 13C NMR (DMSO, 125 MHz) δ 187, 136.3, 135.4, 126.8,
125.9, 123.0, 115.1, 114.7, 112.6, 44.1. MS (ESI) 252/254 [M+H]+.
4.4.8. 8-keto-N,N,N-trimethyltryptamine (13)—To a solution of 8-keto-tryptamine (10)
in KHCO3-saturated MeOH, 3 equivalents of methyl iodide were added and stirred
overnight. The product mixture under these conditions contained unreacted starting material
(10), 13, 14, and a minor amount of the single methyl analog which were separated by
reverse phase HPLC. Using excess MeI (> 5 eq) yields exclusively the quaternary amine
product. Yellow solid; 1H NMR (DMSO 600 MHz) δ 8.51 (1H, s), 8.15 (1H, d J = 7.3 Hz),
7.57 (1H, d J = 7.3 Hz), 7.24 (2H, m), 4.93 (2H, s), 3.32 (9H, s). 13C NMR (DMSO, 150
MHz) δ 184.9, 137.4, 136.5, 125.4, 123.3, 122.4, 121.0, 114.6, 113.1, 66.05, 53.5.
HAESIMS m/z 217.1327 [M+H]+ (cald for C13H17ON2, 217.1341)
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4.4.9. 6-bromo-8-keto-conicamin (2a)—See above procedure for 13, but using
compound 11 as starting material. The product mixture primarily contained 2a and 14,
which were seprable by reverse phase HPLC. Off-white crystalline solid; 1H NMR (DMSO
600 MHz) δ 8.51 (1H, s), 8.07 (1H, d J = 8.41 Hz), 7.78 (1H, s), 7.35 (1H, d J = 8.46 Hz),
4.90 (2H s), 3.31 (9H, s). 13C NMR (DMSO, 150 MHz) δ 184.6, 139.5, 138.2, 125.0, 124.8,
122.5, 116.1, 115.5, 114.5, 66.1, 53.5. HAESIMS m/z 295.0443 [M]+ (calcd for
C13H16N2O79Br, 295.0441).
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4.4.10. 5-bromo-8-keto-conicamin (3)—See above procedure for 13, but using
compound 12 as starting material. The product mixture primarily contained 3 and 15. Offwhite crystalline solid; 1H NMR (DMSO 600 MHz) δ8.52 (1H, s), 8.27 (1H, s), 7.54 (1H, d,
J = 8.3 Hz), 7.34 (1H, d, J = 8.0), 4.91 (2H, s), 3.32 (9H, s). 13C NMR (DMSO, 150 MHz)
δ184.4, 138.8, 137.6, 127.7, 125.4, 123.0, 115.6, 114.8, 114.0, 66.0, 53.5. HAESIMS m/z
295.0442 [M]+ (calcd for C13H16N2O79Br, 295.0441)
4.4.11. 6-bromo-8-keto-N,N-dimethyltryptamine (14)—See above procedure for 13,
but using compound 11 as starting material. 1H NMR (DMSO 600 MHz) δ12.26 (1H, s),
8.45 (1H, s), 8.10 (1H, d, J = 8.5 Hz), 7.68 (1H, s), 7.31 (1H, dd, J = 8.4, 1.4 Hz), 3.52 (2H,
s), 2.26 (6H, s) 13C NMR (DMSO, 150 MHz) see supplemental Figs. S29 and S30.
HAESIMS m/z 281.0285 [M+H]+ (calcd for C12H14N2O79Br, 281.0290)
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4.4.12. 5-bromo-8-keto-N,N-dimethyltryptamine (15)—See above procedure for 13,
but using compound 12 as starting material. 1H NMR (DMSO 600 MHz) δ8.46 (1H, s), 8.30
(1H, bs), 7.46 (1H, d, J = 8.6 Hz), 7.32 (1H, broad d, J = 8.6 Hz), 3.51 (2H, s), 2.26 (6H, s)
13C NMR (DMSO, 150 MHz) see supplemental Figs. S32 and S33. HAESIMS m/z
281.0287 [M+H]+ (calcd for C12H14N2O79Br, 281.0290)
4.4.13. 8-oxo-N,N-dimethyltryptamine (16)—See above procedure for 13. 1H NMR
(DMSO 600 MHz) δ 11.98 (1H, s), 8.42 (1H, d, J = 2.7), 8.17 (1H, d, J = 7.9 Hz), 8.15 (1H,
d J =7.29 Hz), 7.47 (1H, d, J = 7.7 Hz), 7.20 (1H, td, J = 7.7, 7.1, 1.5 Hz), 7.17 (1H, td, J =
7.9, 7.0, 1.3 Hz), 3.52 (2H, s), 2.27 (6H, s). 13C NMR via HMBC (DMSO, 150 MHz) δ
192.9, 136.2, 135.9, 125.6, 122.6, 121.6, 121.3, 115.0, 112.1, 66.4, 45.4. HAESIMS m/z
203.1179 [M+H]+ (cald for C12H15ON2, 203.1184)
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4.5. Cytotoxic assays

Author Manuscript

Extract C011027 was evaluated in the in vitro disk diffusion soft agar colony formation
assay which defines differential cell killing among 13 cell types. The screen includes CCRFCEM (leukemia), H125 (lung cancer), OVCAR-5 (ovarian cancer), MCF-7 (breast cancer),
PANC-1 (pancreatic cancer), U251N (brain cancer), as well as a normal murine
hematopoietic progenitor cell, CFU-GM. The human cancer cell lines are maintained in cell
culture in either Dulbecco’s modified MEM, Eagles MEM or RPMI-1640 depending upon
the cell lines. The media is supplemented with either 10% or 15% BCS plus Pen-Strept
(100,000 I.U. Pen/L; 100,000 μg/L Strept) and L-glutamine (292 mg/L). Cells are removed
from cultures by a trypsin solution (0.05%). Plating efficiencies are sufficiently high that
30,000 to 60,000 cells in 3 mL produce the desired number of colonies (over 10,000 per
plate) in 60 mm plates. This soft agar top layer (0.3% with the serum and media as above)
plus the titrated tumor cells are poured into plates and allowed to solidify. A volume of 15
μL of each sample is dropped onto a 6.5 mm disk (Whatman filter disks). The disk is
allowed to dry overnight and then placed close to the edge of the petri dish. The plates are
incubated for 7–10 days (depending upon cell type) and examined by an inverted stereomicroscope (10×) for measurement of the zone of inhibition measured from the edge of the
filter disk to the beginning of normal-sized colony formation. The diameter of the filter disk,
6.5 mm, and a difference in zones between solid tumor cells and either normal or leukemia
cells of 6.5 mm or greater defines solid tumor selective compounds. If the test material is
excessively toxic at the first dosage, a range of dilutions of the agents (at 1:4 decrements) are
tested against the same tumors. At some dilution, quantifiable cytotoxicity is invariably
obtained.
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IC50 assays were performed as follows. PANC-1 human pancreatic cancer (epithelioid
carcinoma) cells are plated at 5×104 cells in T25 tissue culture flasks (Falcon Plastics, New
Jersey) with 5 mL media RPMI 1640 (Cellgro, Virginia) supplemented with 15% BCS
(Hyclone, Utah), 1% Penicillin-Streptomycin, and 1% Glutamine (Cellgro). Three days later
(cells in logarithmic growth phase), test compounds are added to the flasks to achieve
concentrations ranging from 100 to 10−5 μg/mL (10-fold dilutions). Seventy-two hours later,
the cells in the flasks are washed, trypsinized, spun down and counted for both viable and
dead cells using 0.04% trypan blue (Gibco, Maryland). Viable cell number as a function of

Tetrahedron. Author manuscript; available in PMC 2019 January 11.

Lorig-Roach et al.

Page 10

Author Manuscript

concentration is plotted and the IC50 value determined by interpolation. Each point is done
in duplicate and a standard deviation determined. A second, definitive run is then carried out
with four two-fold drug dilutions around the initial IC50 value and these are the IC50 values
reported in Table 2.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

The major products, 1 and 2, isolated from Oceanapia sp. C011027 and the 5-Br synthetic
analog 3.
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Using NMR data to rapidly distinguish between 5- vs. 6-Br indole frameworks when the
diagnostic NOEs to the NH cannot be observed. aThis work; bSeagraves;10 cBartik.9
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Fig. 3.

Other natural products featuring halogenated indole with a quaternary amine moiety.
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Scheme 1.

Synthesis of the natural product 6-Br-8-keto-conicamin (2a) and nine key analogs 3, 8, and
10–16 for in vitro cytotoxicity screening against the PANC-1 tumor cell line. Following the
synthetic route to 11 from 5 enabled facile differentiation between the 5- and 6-bromo
isomers 11 and 12 synthesized from 10. The spectral and biological properties of 2a, 11, or
14 derived from 5 were equivalent to those derived from 10.
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Chart 1.
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Overview of the campaign involving: sample acquisition, extraction, prefractionation, and
Disk Diffusion Assay (DDA) for solid tumor selectivity against five human tumor cell lines.
The work flow also involved dereplication and structure elucidation by accurate MSn and
NMR spectroscopy along with SAR biological evaluation of natural products and synthetic
analogues.
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Disk diffusion assay zone of inhibition data for the parent Oceanapia sp. C011027 extract, synthetic 2a, various indole analogs of 2, and therapeutic
standards compared across five solid tumor cell lines, a leukemia line (CEM), and bone marrow progenitor cells (CFU-GM). Bold numbers indicate
selectivity, defined as a differential zone of inhibition greater than 7 mm between solid tumor cell line and at least one normal cell proxy (CEM/CFUGM).
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7.77, bs

124.3, C

122.7, CH

125.4, CH

115.9, C

115.6, CH

138.1, C

185.4, C

66.1, CH2

53.5, CH3

3a

4

5

6

7

7a

8

9

N-(CH3)3
3.33, s

4.99, s

–

–

7.39, dd (1.3, 8.5)

8.08, d (8.5)

–

9

8, N-(CH3)3

3a, 5, 6, 7a

3a, 7

3, 3a, 5, 7, 7a

3, 3a, 7a

HMBCc

Carbon type determined by gHSQC;

53.5

66.1

184.6

139.5

116.1

115.5

125.0

122.5

124.8

114.5

138.2

δC

3.31, s

4.90, s

–

–

7.78, bs

–

7.35, bd (8.5)

8.07, d (8.5)

–

–

8.51, s

8.51, s

δH, mult (J, Hz)

2a

53.5

66.0

184.4

137.6

114.8

125.4

115.6

123.0

127.7

114.1

138.8

δC

3.32, s

4.91, s

–

–

7.54, d (8.6)

7.34, d (8.4)

–

8.27, s

–

–

8.52, s

8.54, s

δH, mult (J, Hz)

3

c
gHMBC(AD) correlations to indicated carbon with JnCH optimized for 6 Hz couplings and using a two second relaxation delay.

b

Measured at 600 MHz (1H) and 150 MHz (13C);

a

–

114.6, C

3

–

8.58, bs

136.9, CH

2

δH, mult (J, Hz)
8.47, bs

δC, Typeb

1

position

2

NMR Dataa (DMSO-d6) for natural 6-Br-8-keto-conicamin A (2), synthetic 6-Br-8-keto-conicamin (2a), and synthetic 5-Br-8-keto-conicamin A (3).
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In vitro IC50 values against the PANC-1 cell line for natural 2, synthetic 2a, other synthetic analogs, and two
therapeutic standards.
PANC-1 IC50 (μM)

Compound
6-Br-conicamin (1)

NA

6-Br-8-keto-conicamin A (2) [natural product]

1.5

6-Br-8-keto-conicamin A (2a) [synthetic product]

4.1

Author Manuscript

5-Br-8-keto-conicamin A (3)

5.8

1H-indole-3-carbonyl cyanide (8)

NA

8-keto-tryptamine (10)

NA

6-Br-8-keto-tryptamine (11)

NA

5-Br-8-keto-tryptamine (12)

NA

N,N,N-trimethyl 8-keto-tryptamine (13)

23

6-Br-N,N-dimethyl-8-keto-tryptamine (14)

NA

5-Br-N,N-dimethyl-8-keto-tryptamine (15)

NA

N,N-dimethyl-8-keto-tryptamine (16)

NA

5-fluorouracil
gemcitabine

5.714; 7.0
7.215; 0.02*

NA – compounds inactive in soft-agar disk diffusion assay as shown in Table 1

*

Note that this IC50 was determined after 5 days compared to 48 hr. We have found in our lab (unpublished data) that there is ~250-fold difference

in IC50 values between a 24 hr and a 5-day assay for gemcitabine.
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